Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world studyPRNewsWire • 08/26/26
Lilly's GLP-1 pill hits UK pharmacies as US battle with Novo intensifiesProactive Investors • 08/24/26
Prediction: Eli Lilly Could Be One of the Biggest Winners of the Next Decade. Here's Why.24/7 Wall Street • 08/23/26
Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear WinnerInvestors Business Daily • 08/21/26
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy PointInvestors Business Daily • 08/21/26
There's a Black Market for Eli Lilly's Unapproved GLP-1 Drug. Here's Why That's BullishThe Motley Fool • 08/20/26
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?Zacks Investment Research • 08/19/26